The Jackson Laboratory Knockout Mouse Production and Phenotyping Project (JAX KOMP2)

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 3UM1OD023222-10S1

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2011
    2021
  • Known Financial Commitments (USD)

    $925,466
  • Funder

    National Institutes of Health (NIH)
  • Principal Investigator

    Robert E Braun
  • Research Location

    United States of America
  • Lead Research Institution

    Jackson Laboratory
  • Research Priority Alignment

    N/A
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Disease models

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

PROJECT SUMMARYIn response to "NOT-RM-20-015", we propose an urgent competitive revision to The Jackson LaboratoryKnockout Mouse Phenotyping Project (KOMP2) to develop the next generation of precision mouse models formechanistic discovery of SARS-CoV2 infection and therapeutic discovery of COVID-19 disease treatments.The worldwide response to the COVID-19 pandemic has triggered a surge in demand for animal models tounderstand the underlying biology and pathology of SARS-CoV-2 infection and for the preclinical developmentof novel therapeutic strategies. Several mouse models have recently been reported that respond with varyingdegrees to SARS-CoV-2 infection. However, given the diversity of patient outcomes, any one mouse model ona standard inbred genetic background does not reflect the impact of host genetic context on SARS-CoV-2infection and response to treatment. We therefore propose to create a second-generation mouse modelplatform incorporating diverse genetic backgrounds, to characterize the variation in SARS-CoV-2 infectiondynamics and the development of clinically-relevant disease. The proposed project will rapidly provide theresearch community with an urgently needed resource for linking the variability in COVID-19 disease outcomewith underlying host genetic features, and for developing precision therapies tailored to treat the individualpatient. Our Specific Aims are: 1) To create a panel of genetically diverse transgenic models for SARS-CoV-2infection; 2) To characterize infectivity, phenotypic response, disease outcome, and transcriptomeheterogeneity of these models; and 3) To distribute these models and our outcome data to the scientificcommunity.